Translational Development Acquisition Q2 FY26 net income falls 41.66% to $946,982; trust account dividends slip 10.87% to $1.64 million
TDAC•Quarterly and half-year results
- Translational Development Acquisition posted Q2 net income of $946,982, down 41.66% from a year earlier.
- Dividends on trust-held marketable securities fell 10.87% to $1.64 million; results also included a $36,138 unrealized loss.
- General and administrative costs climbed to $661,050 from $221,127, pressuring quarterly profit.
- For the first half, net income slipped 26.62% to $2.28 million on $3.28 million of trust dividends.
- TDAC agreed to a $50 million share subscription tied to its planned ProLogium deal; trust assets totaled $157.26 million at June 30.
